Monobactam organic compounds for the treatment of bacterial infections

US10369138B2 · kind B2 · utility

Assignee

• Novartis AG · CH

Inventors

• Virender Singh Aulakh · Whitehorse, CA
• Anthony Casarez · Princeton, US
• Xiaodong Lin · Walnut Creek, US
• Mika Lindvall · Emeryville, US
• Glenn McEnroe · San Mateo, US
• Heinz Ernst Moser · San Mateo, US
• Folkert Reck · Walnut Creek, US
• Meiliana Tjandra · Dublin, US
• Robert Lowell Simmons · San Francisco, US
• Aregahegn Yifru · Benicia, US
• Qingming Zhu · Walnut Creek, US

Key dates

• Filing date: Sep 22, 2015
• Grant date: Aug 6, 2019
• Expiry date: Feb 25, 2038

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

This invention pertains generally to antibacterial compounds of Formula I, as further described herein, and pharmaceutically acceptable salts and formulations thereof. In certain aspects, the invention pertains to methods of using such compounds to treat infections such as those caused by Gram-negative bacteria.